Stocktoria
Maze Therapeutics, Inc. MAZE
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2025-01-31
Maze Therapeutics, Inc. financials (annual)
Bars are annual figures from 2024 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 |
|---|---|---|
| Revenue | — | $167.5M |
| R&D expense | $108.4M | $83.5M |
| Operating income | -$142.9M | $57.6M |
| Income tax | $0 | $1.2M |
| Net income | -$131.1M | $52.2M |
| EPS (diluted) | $-3.05 | $1.25 |
| Operating cash flow | -$111.9M | $76.0M |
| Free cash flow | -$112.7M | $74.8M |
| Cash & equivalents | $189.2M | $196.8M |
| Total assets | $397.1M | $240.5M |
| Total liabilities | $42.2M | $43.6M |
| Shareholders' equity | $355.0M | -$311.2M |
Growth · year-over-year
| Metric | FY2025 | FY2024 |
|---|---|---|
| Net income growth | -351.0% | — |
| EPS growth | -344.0% | — |
| Free cash flow growth | -250.7% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.